Journal of the European Academy of Dermatology and Venereology· 2013Q1
Behçet Hastalığı Uluslararası Kriterleri (ICBD): yeni kriterlerin duyarlılık ve özgüllüğü üzerine 27 ülkeden ortak bir çalışma
The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria
- 1.462atıf
- Q1SCImago
- 2013yıl
Kısa özet
Yeni Behçet Hastalığı Uluslararası Kriterleri (ICBD), mevcut kriterlere (85.0%) kıyasla önemli ölçüde daha yüksek duyarlılık (%94.8) ve makul bir özgüllük (%90.5) sergilemektedir. Bu kriterler, 27 ülkeden 2556 hasta ve 1163 kontrol verileri kullanılarak geliştirilmiştir.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Yeni ICBD kriterleri belirli semptomlara puan atar: oküler/oral/genital lezyonlar (2 puan), deri/CNS/vasküler (1 puan), paterji testi (1 puan).
- ≥4 puan alan bir hasta Behçet hastalığı olarak sınıflandırılır.
- ICBD, doğrulama aşamasında %94.8 duyarlılık ve %90.5 özgüllük elde ederek ISG kriterlerini (85.0% duyarlılık) geride bırakmıştır.
- Kullanıldığında paterji testi, özgüllükte minimal bir azalmayla duyarlılığı %98.5'e kadar artırabilir.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
OBJECTIVE: Behçet's disease (BD) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test. Low sensitivity of the currently applied International Study Group (ISG) clinical diagnostic criteria led to their reassessment. METHODS: An International Team for the Revision of the International Criteria for BD (from 27 countries) submitted data from 2556 clinically diagnosed BD patients and 1163 controls with BD-mimicking diseases or presenting at least one major BD sign. These were randomly divided into training and validation sets. Logistic regression, 'leave-one-country-out' cross-validation and clinical judgement were employed to develop new International Criteria for BD (ICBD) with the training data. Existing and new criteria were tested for their performance in the validation set. RESULTS: For the ICBD, ocular lesions, oral aphthosis and genital aphthosis are each assigned 2 points, while skin lesions, central nervous system involvement and vascular manifestations 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD. In the training set, 93.9% sensitivity and 92.1% specificity were assessed compared with 81.2% sensitivity and 95.9% specificity for the ISG criteria. In the validation set, ICBD demonstrated an unbiased estimate of sensitivity of 94.8% (95% CI: 93.4-95.9%), considerably higher than that of the ISG criteria (85.0%). Specificity (90.5%, 95% CI: 87.9-92.8%) was lower than that of the ISG-criteria (96.0%), yet still reasonably high. For countries with at least 90%-of-cases and controls having a pathergy test, adding 1 point for pathergy test increased the estimate of sensitivity from 95.5% to 98.5%, while barely reducing specificity from 92.1% to 91.6%. CONCLUSION: The new proposed criteria derived from multinational data exhibits much improved sensitivity over the ISG criteria while maintaining reasonable specificity. It is proposed that the ICBD criteria to be adopted both as a guide for diagnosis and classification of BD.
Yazarların özeti; kaynağından alınmıştır. Journal of the European Academy of Dermatology and Venereology, 2013 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Oftalmoloji (Göz Hastalıkları)
OphthalmologyMedicine